Mechanistic Insights into Deoxynivalenol-Induced Liver Injury: The Interplay Between Mitophagy and Antioxidant Defense

Study Background and Research Question

Deoxynivalenol (DON), produced by Fusarium species, is a resilient mycotoxin contaminant commonly found in cereals and animal feed across the globe. Its prevalence—ranging from 64% to 98% in various food and feed samples—poses a significant risk to human and animal health due to its chemical stability and persistence in the environment. Upon ingestion, DON accumulates rapidly in the liver, the primary site for metabolic detoxification, thereby exposing hepatocytes to its toxic effects. While liver damage from DON exposure has been reported, the precise molecular mechanisms driving hepatotoxicity remain incompletely understood. The reference study (Cao et al., 2025) investigates the hypothesis that DON-induced liver injury is mediated by dysregulated mitophagy and suppression of the p62-Keap1-Nrf2 pathway, both critical for cellular homeostasis and defense.

Key Innovation from the Reference Study

The central innovation of this research lies in its elucidation of a dual-pathway mechanism by which DON induces hepatotoxicity. Specifically, the study demonstrates that DON exposure results in overactivation of PINK1/Parkin-mediated mitophagy, leading to excessive clearance of mitochondria and triggering mitochondrial dysfunction. Simultaneously, DON suppresses the cytoprotective p62-Keap1-Nrf2 signaling axis, weakening the cell's antioxidant response. The convergence of these two effects amplifies oxidative stress, apoptosis, inflammation, and lipid metabolism disorder in hepatocytes. These findings clarify the sequence of molecular events underlying DON-induced liver injury and highlight potential intervention points for mitigating toxicity (reference).

Methods and Experimental Design Insights

The study employed a combination of in vivo and in vitro approaches. Mice were administered DON at doses of 0–4.8 mg/kg for seven days to model subacute exposure, while the immortalized normal mouse hepatocyte line AML-12 was treated with DON at concentrations up to 6.4 μM for 24 hours. Liver injury was assessed through histopathological examination, biochemical assays for serum liver enzymes, and molecular analyses of apoptosis, oxidative stress, and inflammation markers. To dissect the role of mitophagy, the authors used Mdivi-1 (a mitophagy inhibitor) and siRNA-mediated knockdown of PINK1. The function of the p62-Keap1-Nrf2 pathway was probed via p62 overexpression, and subsequent effects on Nrf2 nuclear translocation and antioxidant gene expression were quantified.

Protocol Parameters

• Animal model DON exposure: 0–4.8 mg/kg, oral gavage, daily for 7 days (reference study protocol).
• Cell line treatment: AML-12 cells exposed to 0–6.4 μM DON, 24 hours.
• Mitophagy inhibition: Mdivi-1 administered according to manufacturer instructions, or PINK1 knocked down by specific siRNA (workflow-specific concentrations).
• p62 overexpression: Transfection with p62-expressing plasmid, followed by validation of expression and downstream pathway activation.
• Assessment endpoints: Mitochondrial membrane potential, apoptosis assays, oxidative stress indicators (e.g., ROS measurement), qPCR/Western blot for Nrf2 pathway targets.

Core Findings and Why They Matter

The study's core findings establish that DON exposure leads to:

• Overactivation of PINK1/Parkin-mediated mitophagy: Excessive clearance of mitochondria impairs energy metabolism and increases susceptibility to apoptosis and oxidative damage.
• Suppression of the p62-Keap1-Nrf2 pathway: Diminished Nrf2 nuclear translocation reduces the transcription of antioxidant genes, lowering the cell’s defense against oxidative stress.
• Amplified hepatocyte injury: The combination of mitochondrial dysfunction and impaired antioxidant response results in heightened apoptosis, inflammation, and lipid dysregulation.
• Protective effect of p62 overexpression: Restoring p62 levels competitively binds Keap1, releases Nrf2, and enhances antioxidant defense, thereby mitigating DON-induced injury (Cao et al., 2025).

These results clarify the dual mechanistic basis for DON hepatotoxicity and suggest that strategies targeting mitophagy modulation or Nrf2 pathway activation may be viable for intervention.

Comparison with Existing Internal Articles

Several recent internal articles reinforce and contextualize these findings. For example, "Deoxynivalenol-Induced Liver Injury: Mitophagy and Nrf2 Disruption" and "Mitophagy and Nrf2 Pathway Disruption" provide convergent evidence that DON-induced liver injury proceeds through overactivation of mitophagy and concurrent suppression of the cytoprotective Nrf2 axis. These resources echo the mechanistic framework proposed in the reference study, underscoring the importance of both mitochondrial quality control and antioxidant regulation in hepatotoxicity models. Furthermore, workflow-oriented guides such as "Applied Workflows with Anti-ROR1 Antibody (Zilovertamab)" illustrate how robust signaling inhibition strategies—though focused primarily on cancer and liver injury models—can inform the design of functional assays for pathway analysis, including Wnt5a-induced ROR1 signaling inhibition and related mechanistic studies.

Limitations and Transferability

While the reference study provides a robust mechanistic framework, several limitations merit consideration. The work focuses on subacute DON exposure in mice and AML-12 cells, which may not fully recapitulate chronic or species-specific responses encountered in human populations. The reliance on pharmacologic inhibitors and overexpression systems, while informative, may introduce off-target effects or non-physiological levels of protein activity. Furthermore, the study primarily addresses early molecular events following DON exposure; the long-term consequences of mitophagy dysregulation and Nrf2 impairment remain to be elucidated. As such, while the mechanistic insights are transferable to other models of hepatotoxicity, further validation in diverse biological systems and eventual translation to human studies are essential for broader applicability (Cao et al., 2025).

Research Support Resources

Researchers aiming to dissect signaling pathways implicated in liver injury, such as Wnt5a-induced ROR1 signaling inhibition or antioxidant response modeling, can enhance their studies with validated reagents suited for ELISA, FACS, and functional assays. For example, the Anti-ROR1 Antibody (Zilovertamab) (SKU F1460) from APExBIO is a humanized monoclonal antibody specifically targeting ROR1, suitable for a range of applications including kinetic studies and animal model research. Its specificity and high purity support reproducible pathway analysis and translational workflow development. Integrating such tools can facilitate rigorous investigation of liver injury mechanisms across different experimental platforms.